News about Market

Innoviva Specialty Therapeutics Signs Licensing Deal with Dr. Reddy's for XACDURO

Innoviva Specialty Therapeutics and Dr. Reddy’s have entered a distribution and licensing agreement to expand access to XACDURO for serious Acinetobacter infections across South and Central America, the Caribbean, Russia, and CIS countries.

Market | 19/06/2026 | By News Bureau |  264

Assertio Announces Completion of Merger with Zydus Lifesciences

Assertio has completed its merger with Zydus Lifesciences, becoming a wholly owned subsidiary of the company. Following the acquisition, Assertio shares have been delisted from Nasdaq, with shareholders receiving USD 23.50 per share in cash.

Market | 19/06/2026 | By News Bureau |  147

Bayer Completes Acquisition of Perfuse Therapeutics

Bayer has completed the acquisition of Perfuse Therapeutics, strengthening its ophthalmology pipeline and expanding its portfolio of innovative eye disease treatments.

Market | 19/06/2026 | By News Bureau |  105

Lupin Launches Azilsartan Medoxomil Tablets in US

Lupin has launched Azilsartan Medoxomil Tablets in the US, a bioequivalent generic version of Edarbi, indicated for the treatment of hypertension in adults.

Market | 17/06/2026 | By News Bureau |  129

Vedana Therapeutics Launches with USD 46 Million Series A Financing for Migraine Therapies

Vedana Therapeutics has launched with USD 46 million in Series A financing to advance next-generation migraine therapies. Backed by migraine experts and investors, the company is developing innovative treatments targeting clinically validated pathways to help patients achieve lasting freedom from migraine.

Market | 17/06/2026 | By News Bureau |  202

Glenmark USA Launches Methylene Blue Injection USP 50 mg/10 mL

Glenmark Pharmaceuticals has launched Methylene Blue Injection USP 50 mg/10 mL, a bioequivalent and therapeutically equivalent generic version of ProvayBlue.

Market | 17/06/2026 | By News Bureau |  102

AviadoBio Broadens vMiX Platform Agreement with King's College London

AviadoBio has expanded its exclusive vMiX Precision Gene Silencing Platform agreement with King’s College London to cover all human therapeutic areas. Backed by positive AVB-406 preclinical data, the RNAi-based platform highlights broad potential for targeted gene therapies.

Market | 17/06/2026 | By News Bureau |  127

Saptalis Launches Cyclosporine Ophthalmic Emulsion

Saptalis Pharmaceuticals has launched Cyclosporine Ophthalmic Emulsion 0.05 percent in 30- and 60-count single-use vials, expanding its ophthalmology portfolio and improving access to high-quality treatment options for patients.

Market | 16/06/2026 | By News Bureau |  108

Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400 mg

Dr. Reddy’s has launched Bosutinib Tablets 400 mg in the US, becoming the first generic equivalent of Bosulif available in the market.

Market | 15/06/2026 | By News Bureau

Teva Completes Acquisition of Emalex Biosciences

Teva has completed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline. The deal supports Teva’s Pivot to Growth strategy.

Market | 12/06/2026 | By News Bureau |  191